The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96, reflecting a -1.72% shift from the previouse trading day's closing. The stock's performance was behind ...

For work, for school, for gaming or a little of everything, here are the best laptops Dell has to offer right now. Matt Elliott is a senior editor at CNET with a focus on laptops and streaming ...

Dell and HP are two of the biggest laptop brands for good reason. They both make plenty of great PCs, and whether you’re buying a laptop for school, work, gaming, everyday productivity, or all ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Vertex (NASDAQ:VRTX) has been running a number of trials because if there’s one thing that we can take away from the failed drug development projects of the past (other than “dang, pain is a ...

Great. Good morning, everyone. Welcome. I'm Jess Fye, Biotech Analyst at J.P. Morgan. We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to ...

VRTX) concerning possible violations of federal securities laws. On December 19, 2024, the company reported disappointing results from its RewinD-LB Phase 2b clinical trial for the pain drug ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s shares closed last Friday at $409.56.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the ...